Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
82 hedge funds and large institutions have $40.9M invested in Evofem Biosciences, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 24 reducing their positions, and 38 closing their positions.
128% more call options, than puts
Call options by funds: $2.94M | Put options by funds: $1.29M
17% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 24
20% less funds holding
Funds holding: 103 → 82 (-21)
45% less capital invested
Capital invested by funds: $74.6M → $40.9M (-$33.6M)
55% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$5.05M |
| 2 |
D.E. Shaw & Co
New York
|
+$4.82M |
| 3 |
Millennium Management
New York
|
+$4.19M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.6M |
| 5 |
Renaissance Technologies
New York
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$16.3M |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
-$4.83M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$4.09M |
| 4 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
-$2.97M |
| 5 |
BlackRock
New York
|
-$2.8M |
EVFM Hedge Fund Activity: Q2 2021 in Review
82 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q2 2021, worth a combined $40.9M — down 45% from $74.6M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of EVFM and 17 opened new positions — a net loss of 21 holders — while 24 trimmed existing stakes and 20 added.
The largest buyer was Morgan Stanley, adding an estimated $5.05M. The largest seller was Invesco, exiting entirely with an estimated $16.3M sold.
- 82 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q2 2021, down from 103 in Q1 2021.
- Funds reported $40.9M of Evofem Biosciences, Inc. Common Stock stock for Q2 2021, down 45% quarter-over-quarter.
- 17 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q2 2021 and 38 closed out, a net change of -21 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q2 2021 was Morgan Stanley, an estimated $5.05M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q2 2021 was Invesco, an estimated $16.3M sold.
Based on aggregated 13F filings for Q2 2021.